PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vaxcyte, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$63.68+0.06 (+0.09%)
Close on Oct 19, 2026
- Market cap
- $9.20B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -74.5% | -25.6% | |
| Return on assets | – | -38.9% | -23.5% | |
| Current ratio | – | 8.30 | 7.91 | |
| Interest coverage | – | -12797.3× | – | |
| Diluted shares | – | 30M | 136M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Vaxcyte generated $1.70B from operations and spent $64.60M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.70B
Used
$64.60M
Capital expenditure$64.60M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$766.63M
- Cash generatingOperating cash flow above zero-$655.58M
- Return on assets improvedROA up on the prior year-33.0% → -21.8%
- Earnings backed by cashOperating cash flow above net income-$655.58M vs -$766.63M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose12.75 → 7.91
- No dilutionShare count did not rise122M → 136M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –